Translocated renal cell carcinoma (tRCC) is a rare and aggressive form of kidney cancer. It accounts for about 5% of all renal cell carcinomas in adults and about 50% in children. Little is known about this cancer subtype, its molecular basis and the best course of clinical treatment. In a new, comprehensive multicenter study of 152 samples, researchers at the Dana Faber Brigham Cancer Center found that genetic changes are rare in tRCC, except for the gene fusion that gave rise to the name tRCC. It helped us discover something and reveal the molecular perspective and clinical characteristics of the disease. .. Their study further suggests that tRCC may respond to treatment with immune checkpoint inhibitors.
Ziad El Bakouny, MD, MSc, the lead author of Brigham’s Internal Medicine Resident, said: “This cancer is so rare that it’s difficult to have Clinical trials Dedicated to it. Comprehensive study of its molecular and clinical features may help develop a better roadmap for treatment. “
The study is published at Cell report..
Ziad Bakouny et al, Integrated Clinical and Molecular characterization of Translocated Renal Cell Carcinoma, Cell report (2022). DOI: 10.1016 / j.celrep.2021.110190
Brigham and Women’s Hospital
Quote: Researchers found a rare form of kidney cancer (January 10, 2022) obtained on January 10, 2022 from https: //medicalxpress.com/news/2022-01-rare-kidney-cancer.html. Sun)
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Researchers shine light on a rare form of kidney cancer Source link Researchers shine light on a rare form of kidney cancer
The post Researchers shine light on a rare form of kidney cancer appeared first on California News Times.